62 results about "Calpain" patented technology

The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.

The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.

Single nucleotide polymorphisms (SNPs) in the gene encoding micromolar calcium activated neutral protease (mu-calpain) effect meat tenderness in bovine. These SNPs correspond to position 18 of exon 9 of Seq. ID No. 3, position 17 of exon 14 of Seq. ID No. 4, and position 185 on intron 19 of Seq. ID No. 4, of the CAPN1 gene encoding mu-calpain. Alleles wherein the SNP at position 18 of exon 9 encodes alanine at amino acid 316 of bovine mu-calpain, the SNP at position 17 on exon 14 encodes valine at amino acid 530 of bovine mu-calpain, and the SNP at position 185 on intron 19 is an cytosine, are all indicative of increased meat tenderness. Any one or all of these SNPs may be used as markers for selecting bovines having superior meat tenderness, and selecting animals for breeding purposes.

The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and / or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.

The invention discloses a high-quality compound feed with low nitrogen and phosphorus emission for Lateolabrax, and aims at providing the high-quality compound feed with low nitrogen and phosphorus emission for the Lateolabrax, which has the advantages of balanced nutrition and low nitrogen and phosphorus emission, and can be used for protecting liver and enhancing immunity. The high-quality compound feed comprises the following components in percentage by weight: 38-46% of steamed fish powder, 29-35% of bean pulp, 15-25% of flour, 1-4% of kelp powder, 2-6% of fish oil, 0.5-1.5% of monocalcium phosphate, 0.01-0.04% of protease, 0.01-0.04% of phytase, 0.2-0.4% of galactooligosaccharide, 0.20-0.35% of choline chloride, and the remaining of additives containing composite vitamin, composite minerals, Vc phosphate, salt, mildewcide and antioxidant. The high-quality compound feed can be widely applied to the field of the cultivation of the Lateolabrax.

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

[Problem]To provide a novel fluorescent probe for detecting the activity of calpain.[Solution]A compound represented by general formula (I) or a salt thereof.

The invention provides methods for diagnosing, preventing, treating, determining the likelihood of developing, or ameliorating a symptom associated with, cardiac disease by administering a therapeutically effective amount of a modulator, such as an inducer, of the posttranslational production of N-terminally truncated forms of cardiac troponin T. An exemplary modulator in the form of an inducer is a Calpain inducer; an exemplary modulator in the form of an inhibitor is an inhibitor of aCalpain inhibitor, such as a mu-Calpain inhibitor.

The present invention relates to a method for treating tissue damage caused by ischemia in a patient which comprises administering to said patient a therapeutically effective amount of a compound which is an inhibitor of cathepsin B or cathepsin L, but which is not as an effective inhibitor of calpain relative to cathepsin B or cathepsin L or both and which compound is a peptidyl diazomethyl ketone.

Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological fluids after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (CSF). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.

The present invention is directed to methods for sustaining eNOS activity to inhibit platelet aggregation, clot retraction, and enhance fibrinolysis. One embodiment of the invention provides methods of treating thrombosis by inhibiting the activity of the syk kinase. Another embodiment provides assays for the discovery of improved compounds to treat thrombosis, by screening for compounds which sustain eNOS activity. Yet another embodiment provides assays for the discovery of improved compounds to treat thrombosis, by identifying inhibitors of calpain and IIbIIIa by screening for compounds which act through calpain or IIbIIIa to sustain eNOS activity. Yet another embodiment provides for enhancing fibrinolysis, by inhibiting the activity of the syk kinase or calpain.

Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein—protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

The invention relates to an expression vector containing a calpain-1 gene. The expression vector comprises a Tet operon, an alpha-MHC promoter nucleotide sequence, a mitochondrial signal peptide sequence and a gene segment of calpain-1 which are connected in sequence. The invention further provides a construction method of an inducible transgenic mouse cardiomyopathy animal model. The constructionmethod comprises the following steps: importing the expression vector containing the calpain-1 gene into oosperms of a mouse, and transferring the oosperms into the uterus of the receptor mouse for gestation, thus obtaining the positive offspring transgenic mouse; and mating the positive offspring transgenic mouse with a transgenic mouse with specific expression of tTA or a transgenic mouse withspecific expression of rtTA, and picking out the inducible transgenic mouse cardiomyopathy animal model from the hybrid offsprings. The invention further discloses applications of the transgenic mousecardiomyopathy animal model obtained through the construction method in screening medicines for treating cardiomyopathy. According to the technical scheme provided by the invention, the modeling success rate is high, the phenotype is stable, the cost is ow, and whether inducting for the generation of cardiomyopathy is needed or not can be selected according to the actual demands.

The invention discloses a determining method for the phosphorylation level of calpain. The determining method includes the steps that 1, the protein concentration of a protein sample containing calpain is adjusted to 5.83-12.5 micrograms / microliter, a phosphorylated antibody is added into the protein sample, the mass ratio of the phosphorylated antibody to the total reacting weight of protein in the protein sample containing calpain is 1 to 1750-2500, then the phophorylated antibody and the protein sample are subjected to vibration hatching at 4 DEG C to form an immune complex, and then through a protein immune precipitation method, a phosphorylated calpain sample is obtained through gathering; 2, through a protein western blot method, the phosphorylation level of the phosphorylated calpain sample obtained in the step1 is detected. Through the protein immune precipitation technology and the western blot technology, phosphorylated calpain in post-slaughter muscles can be detected, the number of needed muscle samples is small, the operation process is simple, repeatability is good, stripes obtained through detection are clear, and the test method is small in potential hurt to the human body.

The invention discloses the stability application of Calpain or the excitant or antagonist of Calpain in preparing AchR aggregate that regulates neuromuscular junction. The invention also discloses a method for screening the agent that regulates the stability of the AchR aggregate of neuromuscular junction by using the Calpain.

The invention discloses a processing method of raw material meat for small crispy meat, and belongs to the technical field of meat processing. The processing method comprises the following steps of S1: rinsing live pigs, performing slaughtering so as to obtain bodies, and performing spraying and disinfecting on the bodies; S2: performing heat bone removing, fat removing and pig skin removing on pig hind legs obtained in the step S1, and injecting a calcium chloride solution of which the concentration is 145-155ppm and the mass is 0.2%-0.5% of that of lean meat to the obtained lean meat; and S3: cooling the lean meat processed in step S1 under minus 40 to minus 35 DEG C for 30-40 minutes, so that thin ice is generated on the surfaces of the lean meat, and then putting the cooled lean meat in a precooling storage of which the temperature is 2-4 DEG C and the humidity is 85-95% for 18-24 hours. According to the processing method disclosed by the invention, the calcium chloride solution isinjected to the hot fresh pig hind legs, so that the activity of calpains in muscles is improved, and the mature of the meat of the pig hind legs is accelerated. The invention further provides a method of preparing the small crispy meat by using the raw material meat. The invention further provides the method for preparing the small crispy meat by using the raw material meat, and the method can realize industrial production of the small crispy meat.

The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases and of calpain. The invention further relates to methods for preventing, treating or managing MMP-related and calpain-related diseases or disorders in mammals comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of said lipophilic diesters of the chelating agent BAPTA.

This invention relates to a method of calcium protease restrain albumen gene 475 place SNP mark filtration of pig, it belongs to domestic animal molecular biology technique field. The procedures includes that distilling of pig gene group RNA, reverse transcription PCR amplification of calcium protease restrain albumen gene, detecting of SNP mark and its correlative analysis to pork tenderness. The feature is that new SNP mark of pig calcium protease restrain albumen gene is separated and determined, one SNP mark propitious to pork is filtrated (475 place C to T), prime used to amplify the place us designed, and kit used for this method is designed. This invention used the correlative characters between the SNP of 475 place in encoding area of calcium protease restrain albumen gene and pork tenderness to provides a new molecule mark method for pig mark assistant selection and matching.

The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and / or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.

The present invention relates to the identification of a single nucleotide polymorphism (SNP) within the bovine CAST locus encoding the calpastatin protein, wherein the allelic variation of the SNP is a G / C transversion associated with post-mortem muscle tenderness. The invention further relates to oligonucleotides useful in identifying the genotype of bovines as it relates to the CAST locus polymorphic site. The invention also encompasses computer-assisted methods and systems for improving the production efficiency for livestock having marketably tender meat using multiple data, and in particular the genotype of the animals as it relates to the CAST SNP. These methods of the invention encompass obtaining a genetic sample from each animal in a herd of livestock, determining the genotype of each animal with respect to specific quality traits as defined by a panel of at least two single polynucleotide polymorphisms (SNPs), one SNP corresponding to a site between exons 5 and 6 of the bovine CAST locus, grouping animals with like genotypes, and optionally, further sub-grouping animals based on like phenotypes.

The invention discloses a preserved meat product preservation method. The method comprises the following steps: (1) screening a culture for fermenting a preserved meat product, and establishing preserved meat fermentation conditions; (2) determining the types and the amount of enzymes and enzymolysis conditions, adding papain, pancrelipase, calpains, pronase and other enzyme preparations into the salting process by taking the texture, flavor, color and the like as indexes, and determining the enzyme addition amount, the enzymolysis time, the enzymolysis temperature and other enzymolysis method conditions; (3) analyzing the acid value and change of peroxide value in the preserved meat production process, and selecting an antioxidant; and (4) preparing an edible film, establishing a coating technology, wherein microbes, the acid value, the peroxide value and the TBA value are used as indexes, different composite edible film materials such as chitosan, modified starch and soy isolate protein are used, and nisin or nisin are added, and performing antiseptic validity treatment on the product by adopting dipping, spraying and other different coating technologies. The method is easy to operate and obvious in effect.

The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.

The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases and of calpain. The invention further relates to methods for preventing, treating or managing MMP-related and calpain-related diseases or disorders in mammals comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of said lipophilic diesters of the chelating agent BAPTA.

Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.

Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological fluids after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (CSF). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.

The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects.

This invention relates to a method of calcium protease restrain albumen gene 1836 place SNP mark filtration of pig, it belongs to domestic animal molecular biology technique field. The procedures includes that distilling of pig gene group RNA, reverse transcription PCR amplification of calcium protease restrain albumen gene, detecting of SNP mark and its correlative analysis to pork tenderness. The feature is that new SNP mark of pig calcium protease restrain albumen gene is separated and determined, one SNP mark propitious to pork is filtrated (1836 place C to T), prime used to amplify the place us designed, and kit used for this method is designed. This invention used the correlative characters between the SNP of 1836 place in encoding area of calcium protease restrain albumen gene and pork tenderness to provides a new molecule mark method for pig mark assistant selection and matching.

The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.

The invention discloses Calpain-1 and application thereof in inhibiting porcine epidemic diarrhea virus infection, and belongs to the technical field of biological engineering. On the basis of finding that pig small intestine mucus total protein can inhibit PEDV infection, the proteinase-1 capable of inhibiting PEDV invasion into host cells is obtained through identification and purification from pig small intestine mucus, the nucleotide sequence of the protein coding gene is as shown in SEQ ID No.1 in a sequence table, and the amino acid sequence of the protein coding gene is as shown in SEQ ID No.2. The porcine calpain protein-1 further obtained through eukaryotic expression also has a remarkable antiviral function, and the porcine calpain protein-1 is mainly used for inhibiting PEDV from invading host cells through enzymolysis of PEDV spike protein. The Calpain-1 disclosed by the invention can also be applied to the preparation of PEDV infection resisting medicines or antiviral feed additives.

A composition comprising a peptide or a peptidomimetic thereof that inhibits the C-terminal domain truncation of mGluR1α by calpain, wherein the peptide is 10-30 amino acids in length and contains a sequence that is at least 70% homologous to VIKPLTKSYQGSGK. Also disclosed are methods of detecting the C-terminal domain truncation of mGluR1α by calpain, methods of inhibiting the C-terminal domain truncation of mGluR1α in a neuron, and methods of identifying a compound that inhibits the C-terminal domain truncation of mGluR1α.